Alex Y Pai1, Cachet Wenziger1, Elani Streja1,2, Donovan A Argueta3, Nicholas V DiPatrizio3, Connie M Rhee1, Nosratola D Vaziri1, Kamyar Kalantar-Zadeh1,2, Daniele Piomelli4, Hamid Moradi5,6. 1. Division of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine School of Medicine, Irvine, California, USA. 2. Tibor Rubin VA Medical Center, Long Beach, California, USA. 3. Division of Biomedical Sciences, University of California Riverside School of Medicine, Riverside, California, USA. 4. Anatomy and Neurobiology, University of California Irvine School of Medicine, Irvine, California, USA. 5. Division of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine School of Medicine, Irvine, California, USA, hamid.moradi@va.gov. 6. Tibor Rubin VA Medical Center, Long Beach, California, USA, hamid.moradi@va.gov.
Abstract
BACKGROUND: Patients with ESRD on maintenance hemodialysis (MHD) are particularly susceptible to dysregulation of energy metabolism, which may manifest as protein energy wasting and cachexia. In recent years, the endocannabinoid system has been shown to play an important role in energy metabolism with potential relevance in ESRD. N-acylethanolamines are a class of fatty acid amides which include the major endocannabinoid ligand, anandamide, and the endogenous peroxisome proliferator-activated receptor-α agonists, oleoylethanolamide (OEA) and palmitoylethanolamide (PEA). METHODS: Serum concentrations of OEA and PEA were measured in MHD patients and their correlations with various clinical/laboratory indices were examined. Secondarily, we evaluated the association of circulating PEA and OEA levels with 12-month all-cause mortality. RESULTS: Both serum OEA and PEA levels positively correlated with high-density lipoprotein-cholesterol levels and negatively correlated with body fat and body anthropometric measures. Serum OEA levels correlated positively with serum interleukin-6 (IL-6) (rho = 0.19; p = 0.004). Serum PEA and IL-6 showed a similar but nonsignificant trend (rho = 0.12; p = 0.07). Restricted cubic spline analyses showed that increasing serum OEA and PEA both trended toward higher mortality risk, and these associations were statistically significant for PEA (PEA ≥4.7 pmol/mL; reference: PEA <4.7 pmol/mL) after adjustments in a Cox model (hazard ratio 2.99; 95% confidence interval 1.04, 8.64). CONCLUSIONS: In MHD patients, OEA and PEA are significantly correlated with variables related to lipid metabolism and body mass. Additionally, higher serum levels of PEA are associated with mortality risk. Future studies are needed to examine the potential mechanisms responsible for these findings and their clinical implications.
BACKGROUND: Patients with ESRD on maintenance hemodialysis (MHD) are particularly susceptible to dysregulation of energy metabolism, which may manifest as protein energy wasting and cachexia. In recent years, the endocannabinoid system has been shown to play an important role in energy metabolism with potential relevance in ESRD. N-acylethanolamines are a class of fatty acid amides which include the major endocannabinoid ligand, anandamide, and the endogenous peroxisome proliferator-activated receptor-α agonists, oleoylethanolamide (OEA) and palmitoylethanolamide (PEA). METHODS: Serum concentrations of OEA and PEA were measured in MHD patients and their correlations with various clinical/laboratory indices were examined. Secondarily, we evaluated the association of circulating PEA and OEA levels with 12-month all-cause mortality. RESULTS: Both serum OEA and PEA levels positively correlated with high-density lipoprotein-cholesterol levels and negatively correlated with body fat and body anthropometric measures. Serum OEA levels correlated positively with serum interleukin-6 (IL-6) (rho = 0.19; p = 0.004). Serum PEA and IL-6 showed a similar but nonsignificant trend (rho = 0.12; p = 0.07). Restricted cubic spline analyses showed that increasing serum OEA and PEA both trended toward higher mortality risk, and these associations were statistically significant for PEA (PEA ≥4.7 pmol/mL; reference: PEA <4.7 pmol/mL) after adjustments in a Cox model (hazard ratio 2.99; 95% confidence interval 1.04, 8.64). CONCLUSIONS: In MHD patients, OEA and PEA are significantly correlated with variables related to lipid metabolism and body mass. Additionally, higher serum levels of PEA are associated with mortality risk. Future studies are needed to examine the potential mechanisms responsible for these findings and their clinical implications.
Authors: María Antón; Alicia Rodríguez-González; Inmaculada Concepción Rodríguez-Rojo; Antoni Pastor; Ángeles Correas; Antonia Serrano; Antonio Ballesta; Francisco Alén; Raquel Gómez de Heras; Rafael de la Torre; Fernando Rodríguez de Fonseca; Laura Orio Journal: Addict Biol Date: 2017-11-27 Impact factor: 4.280
Authors: Jin Fu; Silvana Gaetani; Fariba Oveisi; Jesse Lo Verme; Antonia Serrano; Fernando Rodríguez De Fonseca; Anja Rosengarth; Hartmut Luecke; Barbara Di Giacomo; Giorgio Tarzia; Daniele Piomelli Journal: Nature Date: 2003-09-04 Impact factor: 49.962
Authors: Mark Lucanic; Jason M Held; Maithili C Vantipalli; Ida M Klang; Jill B Graham; Bradford W Gibson; Gordon J Lithgow; Matthew S Gill Journal: Nature Date: 2011-05-12 Impact factor: 49.962
Authors: Harmke A Polinder-Bos; Merel van Diepen; Friedo W Dekker; Ellen K Hoogeveen; Casper F M Franssen; Ron T Gansevoort; Carlo A J M Gaillard Journal: Sci Rep Date: 2018-08-27 Impact factor: 4.379
Authors: Gary Whitlock; Sarah Lewington; Paul Sherliker; Robert Clarke; Jonathan Emberson; Jim Halsey; Nawab Qizilbash; Rory Collins; Richard Peto Journal: Lancet Date: 2009-03-18 Impact factor: 79.321